Horizon Therapeutics USA, INC. (FKA Horizon Pharma USA, INC.)
Based in IL
🤖
AI Overview
With $33.6M in lobbying spend across 25 quarterly filings, Horizon Therapeutics USA, INC. (FKA Horizon Pharma USA, INC.) is one of the biggest lobbying spenders in Washington. Their lobbying covers 3 issue areas. Active from 2018 to 2023.
$33.6M
Total Spend
6
Years Active
1
Firms Hired
6
Lobbyists Deployed
3
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $4.2M |
| 2019 | $4.1M |
| 2020 | $5.8M |
| 2021 | $9.5M |
| 2022 | $6.3M |
| 2023 | $3.8M |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Taxation, Government Issues
- •Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI) and federal program
- •H.R. 1 "Tax Cuts and Jobs Act," all provisions pertaining to business tax reform.
- •S 2039 "Disclosing Foreign Influence Act," all provisions pertaining to the LDA filing exemption.
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The 22,000% ROI
When lobbying spending yields outsized returns.
DOGE vs. the Lobbying Machine
Government efficiency meets the lobbying industrial complex.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.